CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer
NCT07213206
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
1500
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
CDK 4/6 inhibitor combined therapy (omit chemo)
DRUG:
standard of care
Sponsor
Fudan University